Effectiveness guidance document (EGD) for acupuncture research - a consensus document for conducting trials by Witt, Claudia M et al.
CORRESPONDENCE Open Access
Effectiveness guidance document (EGD) for
acupuncture research - a consensus document
for conducting trials
Claudia M Witt1,2*, Mikel Aickin3, Trini Baca4, Dan Cherkin5, Mary N Haan6, Richard Hammerschlag7,
Jason Jishun Hao8, George A Kaplan9, Lixing Lao2, Terri McKay4, Beverly Pierce10, David Riley11, Cheryl Ritenbaugh3,
Kevin Thorpe12, Sean Tunis13, Jed Weissberg14, Brian M Berman2 and Collaborators
Abstract
Background: There is a need for more Comparative Effectiveness Research (CER) to strengthen the evidence base
for clinical and policy decision-making. Effectiveness Guidance Documents (EGD) are targeted to clinical researchers.
The aim of this EGD is to provide specific recommendations for the design of prospective acupuncture studies to
support optimal use of resources for generating evidence that will inform stakeholder decision-making.
Methods: Document development based on multiple systematic consensus procedures (written Delphi rounds,
interactive consensus workshop, international expert review). To balance aspects of internal and external validity,
multiple stakeholders including patients, clinicians and payers were involved.
Results: Recommendations focused mainly on randomized studies and were developed for the following areas:
overall research strategy, treatment protocol, expertise and setting, outcomes, study design and statistical analyses,
economic evaluation, and publication.
Conclusion: The present EGD, based on an international consensus developed with multiple stakeholder
involvement, provides the first systematic methodological guidance for future CER on acupuncture.
Keywords: Comparative effectiveness research, Effectiveness guidance document, Acupuncture
Background
Effectiveness guidance documents (EGDs) provide
specific recommendations about the design of pro-
spective studies that will inform decisions by patients,
clinicians and payers [1]. The recommendations are
targeted to clinical researchers conducting studies of
specific types of interventions or clinical conditions.
EGDs are intended to be analogous to Food and Drug
Administration (FDA) guidance documents in the US,
but are focused on design elements intended to sup-
port clinical and health policy decision-making. The
recommended methods aim to achieve a balance between
internal validity, relevance and feasibility. These docu-
ments are developed through an extensive consulta-
tive process involving a broad range of experts and
stakeholders.
Comparative Effectiveness Research (CER) is the gen-
eration and synthesis of evidence that compares the ben-
efits and harms of different treatment options to
prevent, diagnose, treat, and monitor a clinical condition
or to improve the delivery of care. The purpose of CER
is to assist consumers, clinicians, purchasers, and policy
makers to make informed decisions that will improve
health care at both the individual and population levels
[2]. In addition, the Institute of Medicine (IOM) used
six characteristics to describe CER [3]: 1) Informing
Informs a specific clinical decision from the patient
perspective or a health policy decision from the popu-
lation perspective, 2) compares at least two alternative
interventions, each with the potential to be “best practice”,
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3) describing results at the population and subgroup
levels, 4) measures outcomes—both benefits and
harms—that are important to patients, 5) employs
methods and data sources appropriate for the deci-
sion of interest, 6) is conducted in settings that are
similar to those in which the intervention will be
used in practice.
There is a strong need for additional CER for disor-
ders that are common and costly to society and that
have a great degree of variation in their treatment.[4]
Acupuncture is one of the complementary and alter-
native therapies used for patients suffering from chronic
symptoms, such as pain [5]. Guidelines for designing
and reporting CER involving acupuncture are needed
since acupuncture treatment varies among different
types of providers, states and countries [6], and the
design and results of previous studies have been highly
variable.
“Effectiveness” is a measure of the extent to which
an intervention, when deployed in the field in rou-
tine circumstances, does what it is intended to do
for a specific population [7] and therefore can be of
high relevance to policy evaluation and the health
care decisions of providers and patients. In contrast,
“efficacy” refers to the extent to which a specific
intervention is beneficial under ideal conditions [7].
It is important to note that there is often no sharp
distinction between efficacy and effectiveness trials
[6]. Rather, different dimensions of trial design may
be distributed at varying sites across the continuum.
For randomized trials, the distinction between ex-
planatory and practical or pragmatic is also often
made [8-10]. However, within this document we will
use the more general terms “efficacy” and “effective-
ness” to label both ends of the continuum and a trial
that is more on the effectiveness side would be a
pragmatic trial.
Traditional medical systems such as Chinese medi-
cine frequently use multiple interventions, many of
which are individually complex, e.g. an herbal formula
or an acupuncture point combination. Such complex
interventions, whose components may act additively
or synergistically, are difficult to evaluate. Yet, the as-
pect of CER that addresses effectiveness in a more
everyday practice setting suggests that studies can be
designed to compare real-world whole systems of health
care. The Medical Research Council guidance in the UK
provides the following advice for developing and evaluat-
ing complex interventions [11]:
 A good theoretical understanding is necessary to
understand how the intervention causes change, so
that weak links in the causal chain can be identified
and strengthened.
 Lack of effect may reflect implementation failure
rather than genuine ineffectiveness; a thorough
process evaluation is needed to identify
implementation problems.
 Variability in individual level outcomes may reflect
higher level processes; sample sizes may need to be
larger to take account of the extra variability.
Cluster randomized designs may also be considered.
 A single primary outcome may not make best use of
the data; a range of measures will be needed and
unintended consequences accounted for
where possible.
 Ensuring strict standardization may be
inappropriate; if a specified degree of adaptation to
local settings is allowed for in the protocol, the
intervention may work better.
The aim of the present EGD is to provide comprehen-
sive, consensus-based guidance for future acupuncture
studies by taking existing guidelines into account. This
document should be seen as part of a larger research
framework that would include translational research
strategies to enhance the likelihood that mechanistic
studies, clinical studies and clinical practice will each in-
form and be informed by one another.
Methods
The development of the EGD followed a clear prede-
fined process and included an initial written Delphi
round on the methodological remarks and overall struc-
ture of the document, followed by a one-day consensus
development workshop (July 24, 2011 Santa Fe, USA)
and two written post-workshop Delphi rounds to finalize
the document. Participants of the workshop had follow-
ing background (2 acupuncture patients, 1 health insur-
ance representative, 4 medical doctors (one of them
providing acupuncture), 2 acupuncture practitioners
with Asian background living in the US, 1 nurse, 7
methodologist with background in statistics or epidemi-
ology or neuroscience). Half of them had long-term ex-
perience in acupuncture research. In the consensus
meeting an adapted the “World Café” methodology was
used. The World Café method as developed by Brown
and Isaac is a simple, effective, and flexible format for
hosting large group dialogue [12]. It allows a collabora-
tive dialogue, sharing knowledge, community participa-
tion and suitable for a setting that involves different
stakeholder groups. Participants are asked to sit in one
of several table rounds and discuss 20 to 45 minutes
about one or more predefined questions. At the end of
each round, one person remains at each table as host,
while the other participants move to other tables and
form new groups. Table hosts welcome the newcomers,
summarize the results of the table’s conversation so far
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and ask new questions or go deeper into the original
one. After three or more rounds, the whole group gath-
ers in an auditorium and the table hosts present the
results, all participants explore and discuss emerging
themes and insights, which are captured on flipcharts or
other means. The technique was used in our project in a
more consensus-oriented way by sequentially narrowing
the content of each question to a final decision. The first
group was instructed to brainstorm on the topic, and
come up with principles to answer the question. The
second group debated and refined the principles, and
suggested a few options. The third group made the final
decision based on the deliberations of previous groups.
Each table had a moderator who communicated a con-
cise summary of each group to the next.
In addition, an international review by acupuncture re-
search experts was employed at several stages of the
EGD development process. After the pre-workshop Del-
phi round (before the consensus meeting) and after the
two written post-workshop Delphi rounds the document
was sent to an external international review board in-
cluding eight experts from four countries (US, Germany,
UK, Italy), who did not participate in the consensus de-
velopment workshop.
The consensus process was finalized after all workshop
participants and the external review experts consented.
To allow a comprehensive summary of the recommen-
dations as well as to provide relevant methodological
background information, the results of the consensus were
structured into two parts 1) methodological remarks
and 2) recommendations.
This EGD refers also to the following documents:
 CONSORT for parallel group randomized trials [13].
 CONSORT extension for pragmatic trials [8].
 CONSORT for non-pharmacological trials [14].
 CONSORT extension for cluster randomized trials
[15].
 STRICTA as a CONSORT extension for
acupuncture studies [16].
 SAR Board of Directors White Paper [17].
Results
Methodological remarks
This EGD for acupuncture is the first such document in
the field of Complementary, Alternative and Integrative
Medicine (CAIM) and may serve as a model for other
CAIM interventions. Here we will describe the meth-
odological issues that impact CER in acupuncture
research.
Acupuncture as a complex intervention
Acupuncture is a component of Chinese medicine,
which comprises a “whole medical system” using unique
diagnostic and therapeutic approaches.[6] To date, only
a few studies have evaluated the effectiveness of acu-
puncture as part of a complex Chinese medicine inter-
vention [18]. In addition, acupuncture needling itself
could be seen as just one component of a complex inter-
vention. For research purposes, in their White Paper
[17], the Society of Acupuncture Research Board of
Directors divided the components of acupuncture treat-
ments into the following groups:
 Needling components (i.e., needle size, retaining
time, depth, stimulation, location, frequeny)
 Specific (acupuncture theory-related) non-needling
components that are traditionally considered to have
therapeutic value, for example, in Chinese Medicine
the physical components such as palpation.
 Generic, nonspecific non-needling components that
are not unique to acupuncture treatments, such as
belief and expectations of the practitioner and
patient, therapeutic setting, time and attention.
Research strategy
For the field of complementary medicine, several authors
have highlighted the importance of comparing different
treatment options that reflect usual care [19,20]. Fur-
thermore a research strategy has been suggested aimed
at establishing comparative effectiveness before assessing
component efficacy [20,21]. Using the proposed strategy
will generate evidence relevant to clinical practice. It
will also emphasize the important but sometimes subtle
differences between CAM and conventional medical
practice [21]. From a translational approach, it is recom-
mended that acupuncture should be studied “top down”
in real-world, multi-component “whole-system” trials, as
well as “bottom up” in mechanistic studies that focus on
causal pathways and on understanding how individual
treatment components work and interact [17]. In this
manner, clinical and basic research can inform one an-
other, thereby benefiting clinical relevance and design of
future research.
In order to provide a realistic assessment of treatment
options in a usual care context, CER trials often in-
clude multiple comparison groups, more heterogeneous
patients and longer-term outcomes. CER trials will also
require additional time to engage stakeholders in study
planning and to engage and train participating practi-
tioners working in usual care. Cluster-randomized trials
on acupuncture were recommended as one of the prior-
ities for CER by the IOM [2]. and might help overcome
recruitment problems. Pilot studies are an important in-
strument when planning CER to determine feasibility,
test outcome measures and provide information for
sample size calculation.
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A Bayesian (adaptive) statistical approach might be an
interesting option for real-world CER where it is “nois-
ier” than in “efficacy” studies. Standard statistical (fre-
quentist) techniques to determining study size require
increased sample sizes in effectiveness studies, because
of greater variability and the fact that when comparing
several active treatments relatively small differences are
expected [22]. Designs that use features that change or
“adapt” in response to information generated during the
trial can be more efficient by using formal, probabilistic
statements of uncertainty based on the combination of
all sources of information both from within and outside
a study [22]. For further information see [23].
Research question and the efficacy-effectiveness continuum
When planning a study, it is important to determine the
location on the efficacy-effectiveness continuum. In
other words, should the study be designed primarily to
exclude bias and increase the chance of detecting a spe-
cific effect or to reflect usual care?
Efficacy studies aim to produce results with high in-
ternal validity by reducing both bias (e.g. using blinding)
and variation (e.g. narrow eligibility criteria and a stan-
dardized treatment protocol) to increase the likelihood
of detecting the hypothesized difference. These studies
aim to assess a treatment outcome under “ideal” condi-
tions with highly selected patients. At the other end of
the continuum, results from effectiveness studies aim to
inform decision makers about the potential benefits of
an intervention in a usual care setting, making the
results of the study generalizable and relevant to routine
care by studying patients within the context (methods
and practitioners) in which the acupuncture treatment is
usually deployed.
The place along the continuum is multi-dimensional
and is influenced by the research question [24,25]. Since
there is a range of relevant clinical research questions on
acupuncture, each study context, outcome and design
(e.g. nature of the comparison group) should clearly
reflect the study question.
Possible research questions are:
Specific effect:
– Does acupuncture needling have acupuncture point
specificity (i.e. is needling at real acupuncture points
superior to a penetrating sham procedure at
non-acupuncture points)?
– Does acupuncture needling have a specific effect
(i.e. is needling at real acupuncture points superior
to a non-penetrating sham procedure at
acupuncture points or non-acupuncture points)?
– Does depth of needling, type of stimulation or other
needling parameters have an effect on the outcome?
Acupuncture effect
– Is acupuncture treatment superior or non-inferior
to conventional standard treatment?
– Is acupuncture treatment in addition to usual care
or standard care superior to usual care or standard
care alone?
– What dose (number of treatments) of acupuncture
is needed to see an effect?
Safety and costs
– What are the types and frequency of acupuncture
side effects?
– Is acupuncture treatment cost-effective compared to
another intervention?
Studies that aim only to determine the specific effect
of acupuncture are not part of CER, because sham acu-
puncture is not considered an “active” comparison group
or as a real treatment option. Only trials that compare a
minimum of two treatment options are considered to
represent CER [3]. However, a study that includes a
standard care or usual care comparison group in
addition to a sham acupuncture group can contribute to
CER. There is an ongoing discussion about the chal-
lenges of using sham controls in acupuncture studies
[17,26], which should be considered when planning
those studies. When comparison groups labeled as
“usual care”, “standard care,” or “best practice” are used,
specific details of the interventions should be described.
A helpful tool for planning randomized trials is the PRE-
CIS (pragmatic–explanatory continuum indicator sum-
mary) [10]), which includes the following ten dimensions
that have an influence on the efficacy-effectiveness con-
tinuum: eligibility criteria of participants, flexibility of the
intervention protocol, flexibility of the comparison group
treatment protocol, expertise of the practitioners in
the intervention group, expertise of the practitioners
in the comparison group, adherence of practitioners,
compliance of participants, follow-up intensity, outcome
parameters, and analysis of study population.
Starting from these PRECIS dimensions [10] as well
as the six characteristics of CER developed by the
IOM [3], we propose to structure this guidance docu-
ment a simplified list of five criteria that are most rele-
vant for the study design of CER: participant selection/
eligibility criteria, treatment protocols, practitioner ex-
pertise, outcomes, and setting in which the study is
conducted.
The following paragraphs will introduce the methodo-
logical background for some designs aspects that are
highly relevant for CER on acupuncture.
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Developing the acupuncture and comparison group
interventions
The treatment protocols for the intervention and the
comparison group are central aspects of the study. The
STRICTA guidelines for reporting acupuncture trials
should be taken into account when planning interven-
tion and comparison group treatment protocols [16].
Acupuncture treatment protocol
The acupuncture intervention in CER could be a new
intervention (e.g. new acupuncture style or microsystem)
or an intervention that is already available (e.g. Chinese
style needle acupuncture). When evaluating a new inter-
vention, its characteristics (e.g. dosage, frequency, set-
ting) should reflect the context in which it will be
deployed in the future in a usual care context. When
evaluating acupuncture as an existing intervention that
is widely available for the external validity of the results,
it is important that the treatment protocol of the acu-
puncture group reflects common practice to the extent
possible. However, this could be difficult because of the
large heterogeneity in acupuncture styles and expertise
of the practitioners. Registries (see below) or prospective
observational studies are helpful sources to inform
researchers about practice in usual care. If this informa-
tion is not available, cross-sectional surveys or consensus
procedures with acupuncture experts are the next best
option. However, when selecting the experts participat-
ing in the consensus, their expertise should reflect the
heterogeneity of the acupuncture practised in usual care.
If consensus is lacking before large randomized com-
parative effectiveness studies are performed, pilot studies
comparing different treatments should be considered
[27]. Intervention planning, should also take into ac-
count that acupuncture styles, as well as training and ex-
perience of practitioners can vary considerable in
different states and countries.
Comparison group treatment protocol
The comparison group treatment protocol should be
planned and developed with the same rigor and atten-
tion to detail as the acupuncture intervention. When
standard treatment or usual care is used as the compari-
son group, the treatment components should be
described in the study protocol and detailed usage dur-
ing the study should be documented and reported.
Co-interventions
In CER, co-interventions (e.g. pain medications in pain
trials) are often more heterogeneous than in efficacy
trials, and for understanding the context of the study, it
is relevant to document and report them.
Registries
The Agency for Health Care Research and Quality
(AHRQ) in the US has defined patient registries as an
organized system that uses observational study methods
to collect uniform data (clinical and other) to evaluate
specified outcomes for a population defined by a par-
ticular disease, condition, or exposure, and that serves a
predetermined scientific, clinical, or policy purpose(s)
[28]. Registries are seen as a valuable complement to
randomized controlled trials in determining real-world
outcomes in the practice of medicine and do not gener-
ally have restrictive inclusion or exclusion criteria, nor
do they specify the therapy to which the health care pro-
vider must adhere. They can be used to evaluate out-
comes for diverse purposes ranging from the natural
history of a disease, to the safety of drugs or devices, to
the real-world effectiveness of therapies. These patient
registries are designed to answer predefined questions
by choosing a study design, measurable outcomes, the
study population and analysis. In the registry design, po-
tential sources of bias (systematic error) should be
addressed to the extent that is practical and achievable
[28]. Population-based registries are the most desirable
kind of registry, because they minimize selection of
participants.
Another approach is to use existing data, usually from
the electronic medical records of a well-defined health
care delivery system, for comparative effectiveness re-
search [29]. This line of research tends to use statistical
methods that differ from the clinical trial- based
approaches in AHRQ-type registries, including both pro-
pensity matching for synthetic trial designs and Heck-
man’s selection models [30], but these methods are more
difficult to employ than conventional analyses and meth-
odological problems remain.
An important reason for extending acupuncture CER
research into these domains is the opportunity to evalu-
ate this complex intervention as it is actually practiced,
in the types of patients who are willing to use it, and in
the settings where it is generally used.
Allocation methods
Although CER promotes registries and observational
studies in addition to randomized trials, randomized
studies are still considered the most robust method for
generating comparative effectiveness evidence, as they
are more likely to control for bias and confounding. The
randomized trial will undoubtedly remain an important
component of an advanced CER framework [22]. It is es-
sential that the treatment groups are comparable before
treatment. Randomization as a stochastic method has
historically been the method of choice and is still the
most frequently used method. To prevent selection bias
it is important to conceal the allocation sequence from
Witt et al. BMC Complementary and Alternative Medicine 2012, 12:148 Page 5 of 13
http://www.biomedcentral.com/1472-6882/12/148
those assigning participants to intervention groups, until
the moment of assignment. This prevents researchers
from (unconsciously or otherwise) influencing which par-
ticipants are assigned to a given intervention group [31].
Dynamic allocation procedures could be an alternative
to randomization procedures. Depending on the
study design, they could balance treatment arms across
baseline prognostic factors for clinical trials more effect-
ively than randomization [32,33]. Dynamic allocation
uses algorithms to determine each subsequent patient’s
assignment in a manner that produces the best overall
balance between treatment groups. Design-adaptive allo-
cation methods (minimization) use only patients’ base-
line characteristics to determine the allocation of the
next patient [34]. Assignments using minimization are
more predictable than with randomization, but there are
ways to avoid this (see Taves for rank minimization
[35]). Minimization is gaining more acceptance and was
recognized by CONSORT as an acceptable alternative to
random assignment [36].
Response-adaptive allocation algorithms use both pre-
vious patients’ baseline characteristics and outcomes.
There is a lack of successful studies, especially in acu-
puncture research, using these response-adaptive alloca-
tion approaches.
Although methodologically important, allocation
methods create an artificial context that may influence
the outcome, e.g. they could have a direct impact on the
selection of participants. Treatment preferences that are
influenced by patient expectations are considered a rele-
vant determinant of the placebo effect [37]. For example,
if patients’ preferences have a significant influence on
whether they choose to participate in a study and how
they respond to treatment, the findings of randomized
trials may not apply to those patients who would avoid
participating in trials and instead seek other options in
usual care. Several designs have been developed to inves-
tigate whether preferences matter. The most important
is probably the partially randomized patient preferences
design. In such trials, eligible patients are asked whether
they have a preference for one of the two (or more)
treatments and whether they agree to be randomized.
Those not giving consent to randomization receive the
treatment of their choice, while those without strong
preference are randomized [38]. On an exploratory level
this design provides information about whether the
results observed among randomized patients are differ-
ent from those among patients who were not rando-
mized because of strong treatment preferences. A
number of large acupuncture trials have used variants of
this design, including incentives to motivate patients to
accept randomization [39-43].
Randomization methods including both simple and
stratified randomization could be used to allocate patients
to the treatment groups. Stratified randomization is a use-
ful approach to control for relevant factors for imbalances
in treatment groups. In settings where randomization at
the patient level is not feasible, cluster randomization
might be an option. Cluster trials randomize social units,
such as households, primary care practices, hospital
wards, classrooms, neighborhoods and entire communi-
ties, to different intervention arms. Compared with ran-
domized trials at a patient level, cluster trials have less
statistical power while using the same number of patients
[44]. Because cluster randomization is often applied to
an entire hospital or clinic population without exclusion,
it enhances recruitment and generalizability. Cluster
trials allow resources to be used to best advantage and
due to this they are likely to be less expensive than the
“traditional” randomized controlled trial. However,
cluster-randomized trials also have limitations, for ex-
ample, selection bias can occur and withdrawal drop-out
of whole clusters may seriously affect the validity of the
results. For further guidance on cluster-randomized trials
see [44].
Blinding and expectation
Blinding reduces bias by minimizing the possibility that
the results can be affected by expectations of patients
and practitioners. It is commonly accepted that practi-
tioners cannot be blinded to the acupuncture interven-
tion. In contrast, the intent to blind patients is common
practice in efficacy trials that compare acupuncture with
sham acupuncture, even though data from sham-
controlled acupuncture trials suggest that patients’
expectations might influence the treatment outcome
[45]. Further, patient blinding seems to be impossible
when comparing acupuncture with usual care or stand-
ard care. Thus, in this latter type of CER trial, where nei-
ther practitioner nor patient is blinded and the
outcomes are not assessed by the patient, it is important
to include an assessor for the relevant outcome who is
blinded to the patients’ group assignment. This is not
possible in trials that use patient self-rated outcomes
such as chronic pain measures or quality of life. In such
cases 1) questionnaires sent to the patients’ home or 2)
or blinded telephone interviewers could help to assure
that the practitioners do not influence patients’ outcome
assessments. Another option is to assess patients’ and
practitioners’ expectations and to use them as covariates
when analyzing the data to adjust for different expecta-
tions in the treatment groups.
Health economic evaluations
Over the last few years, health economic data has be-
come increasingly relevant for decision makers faced
with the challenge of reconciling the growing demand
for healthcare services with the funds available [46]. The
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number of economic evaluations of complementary and
integrative medicine has increased over the last few
years and the largest number has been done for acu-
puncture either in addition or compared to routine care
[47]. There are a variety of best practices for performing
economic analyses that should be considered when in-
corporating costs into CER [48].
Recommendations for acupuncture comparative
effectiveness research
These recommendations aim to support optimal use of
resources for generating evidence that will inform stake-
holder decision-making as fully as possible. They are
based on the assumption that it is a conscious decision
of the relevant stakeholders to reduce internal validity in
order to increase generalizability, relevance, feasibility
and timeliness of research results. Multiple stakeholders
were involved in the consensus process for this EGD to
balance aspects of internal and external validity in the
recommendations.
Recommendations developed for the following fields are
summarized in (see also Table 1):
 Designing CER studies
 Treatment protocol, expertise and setting
 Outcomes





a) Involvement of all relevant stakeholders (e.g.
practitioners, clinicians, patients, payers,
researchers) is highly relevant for CER.
b) Identifying relevant topics, planning and design,
and interpreting study results should involve all
relevant stakeholders.
2) Study question and the efficacy-effectiveness
continuum
a) The study question should be clearly phrased, and
include all relevant information about study
participants, interventions, comparison groups and
outcome parameters. In particular, it should clarify
whether the acupuncture treatment is to be
assessed as an “alternative” in direct comparison,
for superiority or non-inferiority, to or as an
adjunctive to a usual or standard care treatment.
b) During the trial planning phase, time should be
given to discuss and determine the trial’s position
in the efficacy-effectiveness continuum for the
following aspects: participant selection/eligibility
criteria, treatment protocol, practitioner expertise,
outcomes, study setting. Using the more detailed




a) In the context of available resources, eligibility
criteria should be as broad as possible. The criteria
should reflect the evidence of the pattern of usage
and disease burden, and the study population
should reflect all well-known relevant disease
characteristics that may interact with the
treatment.
b)Patients with co-morbidities should not be
explicitly excluded from the study enrollment,
with the exception of relevant safety aspects. Both
acupuncture naïve and non-naïve patients should
be enrolled as well.
c) The study disease/condition should be defined as
clearly as possible.
4) Patient recruitment
a) The type of comparator group chosen should
take into account its possible effect on
recruitment success.
b) As far as possible, recruitment strategies should be
similar for all treatment arms and recruitment
should be carried out in places where the
respective treatments are usually employed (e.g.,
both CAM and conventional clinics and
practitioners).
c) Sampling of study participants should be as
systematic as possible, for example, by using
registries or health insurance records and inviting
a random sample or systematic sample of patients
seeking treatment (e.g. every 50th patient) from
the health insurance record list.
d) Patients’ treatment preferences should be
determined and efforts should be made to recruit
both those who express strong treatment
preferences and those who do not.
Treatment protocol, expertise and setting
5)Acupuncture intervention
a) The acupuncture treatment protocol should to
some extent reflect real-world clinical care. If
acupuncture points are predefined, the point
selection should be based on broad systematic
consensus (e.g., expert opinion survey, consensus
meetings and/or textbook survey).
b)Different acupuncture treatment protocols
(standardized, semi-standardized, fully
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individualized) should be compared in a design
with multiple treatment arms.
c) Standardized acupuncture may take Chinese
pattern diagnoses into account by:(1) including
only those patients who have the most frequent
pattern differentiation for the condition of interest,
with treatment protocol tailored to this pattern, or
(2) having different pre-established standardized
treatment protocols for different Chinese pattern
differentiations [49].
6) Comparison groups
a) The treatment protocol for the comparison group
should be based on broad systematic consensus
(e.g., expert opinion survey, consensus meetings
and/or textbook survey).
b) If the terms “usual care”, “standard care” or “best
practice” are used to describe comparison group
treatment, a detailed description must be
provided, stating how these terms are defined
within the trial. In addition, relevant references
should be provided.
7)Treatment documentation
a) All treatments (interventions, co-interventions, over-
the-counter self-medication) carried out in all groups
should be documented. A variety of documentation
methods and sources may contribute details
(including medical records, case report forms, etc.).
Table 1 Checklist for CER relevant aspects for
acupuncture clinical studies
Designing CER studies
Stakeholder involvement □ All relevant stakeholders are involved in
□ Identification of research topic
□ Plan and design of CER
□ Interpretation of results
Efficacy-effectiveness
continuum
□ Study location on the efficacy-effectiveness
continuum is determined for participant
selection/eligibility criteria, treatment
protocol, practitioner expertise, outcomes,
setting in which the study is conducted.
Study population
Eligibility criteria □ Study population reflects those
who usually receive this treatment
□ Study population includes both acupuncture-
naïve and acupuncture-non-naïve patients
Patient recruitment □ Patients are recruited from site where the
treatment is usually employed
Treatment protocol, expertise, and setting
Acupuncture intervention □ Adequate consensus procedure
is used to define intervention
Comparison groups □ Adequate consensus procedure
used to define comparison(s)
□ Definitions and details for terms
such as “usual care” provided
Treatment documentation □ Documentation reflects which treatments
were received in all groups (interventions
and co-interventions)
Outcomes
Measures □ Widely accepted or standardized
outcome measure used
□ Secondary outcomes capture
relevant patient-centered dimensions
for the condition under study
Timing □ Assessment schedule is balanced gaining
study relevant data without substantially
disrupting treatment protocol or setting
Study design and statistical analysis
Allocation □ Allocation is concealed
□ Stratification for subgroups or dynamic
allocation for key characteristics used
Blinding □ Outcome data inaccessible to practitioners
□ Blinded outcome rater, if possible, used
Preferences/ expectation □ Preferences and expectations
measured at baseline
Sample size □ Sample size takes patient heterogeneity
into account
□ Required sample size is feasible
□ Study has enough power for planned
subgroup analyses
Subgroups □ Relevant subgroups preplanned (e.g. gender)
□ Exploratory subgroup analysis
mentioned in study aims
Table 1 Checklist for CER relevant aspects for
acupuncture clinical studies (Continued)
Statistical analysis □ Intention-to-treat analyses planned
□ Relevant subgroup analyses planned
□ Adjusted for stratification variables, baseline
differences and relevant confounders
□ Setting reflects reality in clinical practice
Methodological approach □ Standard methods for economic
evaluations used
□ Sensitivity analysis for all relevant
stakeholder perspectives
□ Relevant subgroups identified
Observation time □ In chronic diseases long-term observation
(≥ 12 months), if possible, planned
Guidelines □ Relevant guidelines (e.g. CONSORT)
consulted and followed
Content □ Stated how and why this is CER
□ Study setting (incl. procedure of
practitioner selection) described in detail
□ Treatment group description from
informed consent provided
□ Comparison groups described in detail
□ Data provided on all interventions
and co-interventions received
□ Relevant subgroup analyses reported




a) If no standard outcome measures for the
respective disease/condition exist, or are not
suitable for CER and no pilot data is available,
pilot studies should be carried out to explore the
value of a broad range of outcomes that may be
sensitive to the condition treated and the
interventions. Qualitative and quantitative
research methods could be combined to identify
all relevant associated outcomes.
b)The main outcome measures should focus on
patient-centered outcomes and, if appropriate,
include relevant biological measures for the
respective disease/condition. Diagnosis-specific
validated standards for outcome measures
published by professional associations (e.g., the
International Headache Society on headache
measures [50]) or expert consensus (e.g., on back
pain measures [10]) should be followed, when
validated for the context of use (e.g. cultural
group), and whenever possible, to permit better
comparison of study results.
c) Multiple primary outcomes addressing distinct
dimensions may be used, if appropriate. This
should be addressed in the sample size calculation
and statistical analysis plan.
d)There is great value in reporting the percentage of
patients with clinically meaningful response for the
main outcome measures, because this information
is easily interpreted by non-scientists.
e) Secondary outcome measures should capture
relevant patient-centered dimensions of the
respective disease/condition (both self-reported and
biological) and might, if appropriate, include
measures of collateral effects (i.e., positive and
negative consequences of the treatment experience,
often seemingly unrelated to the main outcomes).
9) Timing
a) In chronic diseases long-term observations (at
least 1 year) are highly recommended.
b) The use of periodic intervals to document and
compare the trajectory and persistence of treatment
effects is recommended. However, the frequency of
assessment should be balanced, so that relevant
information is gained without major disruptions of
treatment implementations or practice setting.
Study design and statistical analysis
10) Registries
a) The clinical trajectory of individual patients, which
can be tracked by registries, could inform future
acupuncture studies (e.g., as to intervention
details, outcomes, safety, or characteristics of a
usual care population that receives acupuncture
treatment outside of a study situation).
b)When collecting registry data, information should
be obtained from all types of providers who offer
the services of interest.
c) Registries may be useful in identifying frequency of
important potential covariates, including
spirituality and beliefs, prior CAIM use, nutrition,
exercise, etc., but this information is often not
included.
d)Registries could serve as a recruitment platform
for comparative studies.
e) If experience with registries in acupuncture
research is lacking, the development and use of
pilot registries may prove helpful.
11) Allocation methods
a) Use of appropriate allocation methods is strongly
recommended. Randomization at the level of
individual patients is still the method most
frequently used, but dynamic allocation
procedures (e.g. rank minimization [35]) may be
used as an alternative. The final choice depends on
the design of the study as a whole.
b)Stratified randomization or adaptive allocation
techniques may be used to prevent imbalances for
relevant covariates and potential confounders in
study arms.
c) Partially randomized patient preference designs
have an advantage in that they provide additional
exploratory information, whether the results
observed for randomized patients are different
from those not randomized because of strong
treatment preferences. These designs, while adding
potentially important outcomes data to a clinical
trial, are often not feasible because of the need for
much larger sample sizes.
d)Cluster randomization is recommended by the
Institute of Medicine especially for acupuncture
studies and may be used if feasible [2]. When
planning such a trial, it is necessary to consult the
relevant literature and local institutional roles to
determine from whom, when, and how informed
consent must be obtained [51], and to take into
account that a larger sample might be needed than
in patient level randomized trials [44].
e) Standard procedures ensuring allocation
concealment (e.g., central randomization or secure
databases) should be employed. Recommendations
for stratification will be given under point 15.
12) Blinding
a) Blinded outcome measurement (e.g., a blinded
rater) is recommended in order to reduce bias,
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especially for outcomes that are assessed by the
practitioner (e.g. range of motion as a physical
assessment). Methods to minimize the risk of
unblinding (e.g., allocation concealment, rater
training, standardized assessment protocol)
should be employed.
b) Patient-reported trial outcomes data (e.g.,
migraine days, quality of life) should be kept
inaccessible to the practitioner (e.g., by using
sealed envelopes or preferably by sending
questionnaires directly to a study office
independent of the intervention site or using a
blinded interviewer). This should not influence
the symptoms usually reported by the patients
to the practitioner for treatment follow up.
13) Patient preferences and expectation
a) Patient preferences should, if appropriate, be
acknowledged in the study design, e.g., by using a
partially randomized patient preference design. If
such a design is not feasible, then it is important
to document both the patients’ preferences
regarding the treatment options available in the
trial as well as the degree of their knowledge
about these
treatment options.
b) Patient and practitioner preferences and
expectations should be assessed before the
intervention begins (in randomized trials before
randomization).
14) Sample size
a) Sample size depends mainly on the outcome(s) of
main interest and the minimum clinically
important difference (MCID) for the respective
outcome(s).
b) Sample size should account for greater
heterogeneity in CER study populations; because
of this researchers should specifically avoid
conducting small trials (< 50 patients per arm) in
CER, unless there is a specific reason to do such
studies (e.g., pilot studies to test feasibility and
recruitment).
15) Subgroups
a) Relevant subgroups for the disease/condition
under study should be identified based on existing
data and the literature. Subgroup analysis should
be done at least for gender, because there is
preliminary evidence that acupuncture might be
more effective in women than men [52]. Also of
interest are subgroup analyses for different
Chinese pattern diagnoses and for acupuncture
patients, who are naïve/non-naive to acupuncture.
Further analyses could be carried out for age,
ethnicity, disease severity/duration, treatment
preference and recruitment site.
b) The main subgroup analyses should be pre-
specified in the analysis plan and included in
sample size planning for confirmatory testing.
Further subgroup analyses could be done on an
exploratory level, but should be stated as an
objective in the study protocol.
16) Statistical analysis
a) Primary analysis for trials on superiority of
acupuncture should be intention-to-treat. In order
to assess real-world effectiveness of treatments,
benefits and harms should be judged and
compared according to the treatment to which
patients were assigned.
b)Analyses should adjust for relevant potential
confounders (e.g., baseline value of the outcome
measure, stratification variables, expectation).
c) Especially in non-randomized studies (e.g.
observational data from registries), procedures to
compensate for baseline differences must be used
(e.g., matching and/or adjusted analysis).
Economic evaluations
17) Relevance
a) Comparing the effectiveness of treatment options
should be the primary aim of CER, but economic
evaluations should be included whenever possible
as a secondary aim.
b) To allow realistic cost estimates, the setting(s) of
the study should reflect as closely as possible the
real-world clinical practice setting for each
intervention. If a study includes a standardized
and a non-standardized acupuncture arm, it would
be useful to compare their cost-effectiveness.
18) Methodological approach
a) Standard methods for economic evaluations
should be employed, and effectiveness measures
that include both benefits and harms (e.g., utility
measures based on SF-36, SF-12 or EQ-5D)
should be used [48].
b) Sensitivity analysis should include, whenever
possible, different stakeholder perspectives (e.g.,
society, payer and patient). Because acupuncture is
often paid out-of-pocket, the patient’s perspective
is highly relevant.
c) Subgroup analysis should mainly follow the
subgroups defined a priori for the effectiveness
study. A subgroup analysis for gender is
recommended, because there is preliminary
evidence that gender may influence the cost-
effectiveness of acupuncture treatment [53].
d) Exploratory analyses of factors that predict a
better treatment response are suggested to
develop future hypotheses.
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19) Observation time
a) In chronic diseases long-term observations
(at least 1 year) with intermediate measurement
time points are highly recommended, in order to




To ensure that CER on acupuncture will fulfill report-
ing standards, the relevant CONSORT guidelines should
be consulted and followed:
 CONSORT for parallel group randomized trials [13].
 CONSORT extension for cluster randomized trials [15].
 CONSORT extension for pragmatic trials [8].
 CONSORT for non-pharmacological trials [14].
 STRICTA as CONSORT extension for acupuncture
studies [16].
21) Content
a) Publication of a detailed study protocol (design
publication) should take place whenever possible
prior to publication of study results.
b) The study should be registered in an international
accessible trial database with as many details as
possible provided.
c) Publication of the completed study should
describe why and how it qualifies as CER and
make clear the phase of the study.
d) The setting of the study should be described,
including information about the typical usual
care setting in the country where the study was
performed (and if relevant in other countries).
The procedure for selection of practitioners for
each treatment group should be described, with
an account of whether and how those included
in the study differ from the average practitioner
(e.g. training, experience).
e) Wording of treatment group descriptions in the
informed consent should be provided.
f ) If a usual-care or standard-care comparison group
is used, a detailed description with citations
should be included in the intervention section.
g) Detailed results of all treatments, adherence, and
co-interventions in the different groups should be
provided.
h) The most relevant subgroup analyses and analyses
of patient characteristics that predict a better
outcome should be published together with
primary results. Detailed subgroup analysis and/or
de-identified patient level data could be provided
as online files.
Discussion
This is the first EGD in the field of Complementary, Al-
ternative and Integrative Medicine and it offers many
potential benefits. During the development process, a
broader understanding of the unique methodological
aspects of CER emerged in the stakeholder group. CER
studies are intended to improve the external validity of
clinical research to enable decision makers to make
informed decisions. Also, EGDs can contribute to a
more strategic use of limited research resources and
more consistency in trial design.
While other documents provide guidance for publish-
ing studies (e.g. CONSORT statement) EGDs provide
recommendations for the design of future studies.
This acupuncture EGD derived from a systematic de-
velopment process, and the active involvement of differ-
ent stakeholders who have experience with acupuncture
(clinicians, patients, payers and researchers). Further-
more, an additional international expert review with
eight acupuncture research experts from four countries
enhanced the content and quality of the present EGD.
That stakeholders living in Asian countries were not
involved in the development of this EGD might be seen
as a limitation, but to date, CER has had its main focus
in the United States, and is mainly known in Western
countries. In addition, a consensus procedure using a
web-based survey method might have allowed even
broader and more heterogeneous contributions from sta-
keholders in Eastern as well as Western countries. That
this EGD focuses on acupuncture and covers CER for
acupuncture independent of condition treated has the
shortcoming that the recommendations on outcomes
are not at the disease level. However, the aim of this
EGD is to provide a single comprehensive guideline for
future acupuncture research on the seven fundamental
methodological areas: (1) CER study design, (2) treat-
ment protocol, (3) expertise and setting, (4) outcomes,
(5) study design and statistical analyses, (6) economic
evaluation, and (7) publication. The feasibility of the
EGD to design studies was tested in February and April
2012 in two CER research methodology courses with
20–25 participants each, one with US master students
and the other with an international audience of
researchers.
Conclusion
For the first time, the present EGD provides systematic
methodological guidance for future CER on acupunc-
ture. This is the first EGD in the field of Integrative
medicine and further EGDs are planned and many
aspects of this EGD might be transferrable to other non-
pharmacological interventions in the field of comple-
mentary and integrative medicine.
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